Valproic acid and socioeconomic associations in Swedish women with epilepsy 2010-2015.
epilepsy
public health
socioeconomic status
valproic acid
Journal
Acta neurologica Scandinavica
ISSN: 1600-0404
Titre abrégé: Acta Neurol Scand
Pays: Denmark
ID NLM: 0370336
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
12
11
2020
revised:
19
12
2020
accepted:
15
01
2021
pubmed:
2
2
2021
medline:
11
5
2021
entrez:
1
2
2021
Statut:
ppublish
Résumé
We investigated the correlation between socioeconomic status and the prescription of Valproic acid (VPA) in women of fertile age in Sweden. This is a registered-based cohort study including all women living in Sweden aged 18-45 years in the years 2010-2015, with a diagnosis of epilepsy and no intellectual disability (n = 9143). Data were collected from the National Patient Register, the Drug Prescription Register, and the Longitudinal integration database for health insurance and labor market studies (LISA). Women with only 9 years of school were more often prescribed VPA than women with a University degree (12.9% compared to 10.7% in 2015 [p = 0.015]). Similar differences were seen between the lowest and highest income group (16.6% compared to 12.7% in 2015 [p < 0.001]). The odds of having a VPA prescription in 2015 was 1.59 (p < 0.001) in women with 9 years of school compared to women with a University degree, and 1.60 (p < 0.001) in the lowest income group relative to the highest income group after adjusting for age. From 2010 to 2015, the proportion with VPA prescription in the whole cohort diminished with an absolute reduction of -2.2% (p < 0.001). The decrease was similar among the different education and income groups (p = 0.919 and p = 0.280). The results indicate that the increased knowledge on VPA teratogenicity was implemented across socioeconomic strata in the Swedish healthcare system. Women with lower income or education level remained more frequent VPA users. Whether this difference reflects epilepsy type or severity, or socioeconomic disparities, merit further study.
Substances chimiques
Anticonvulsants
0
Valproic Acid
614OI1Z5WI
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
383-388Subventions
Organisme : The Sahlgrenska Academy at the University of Gothenburg through the LUA and the ALF agreement Vastra Gotalandsregionen
Organisme : Margarethahemmet foundation
Organisme : Swedish government's Agreement for Medical training and Research
Organisme : NEURO Sweden
Organisme : Svenska Sällskapet för Medicinsk Forskning
Informations de copyright
© 2021 The Authors. Acta Neurologica Scandinavica published by John Wiley & Sons Ltd.
Références
Begley CE, Basu R, Reynolds T, Lairson DR, Dubinsky S, Newmark M, et al. Sociodemographic disparities in epilepsy care: results from the Houston/New York City health care use and outcomes study. Epilepsia. 2009;50(5):1040-1050.
US Centers for Disease C, Prevention Epilepsy P. About one-half of adults with active epilepsy and seizures have annual family incomes under $25,000. Epilep Behav. 2016;58:33-34.
Rubinger L, Chan C, Andrade D, Go C, Smith ML, Snead OC, et al. Socioeconomic status influences time to surgery and surgical outcome in pediatric epilepsy surgery. Epilep Behav. 2016;55:133-138.
Andersson K, Ozanne A, Edelvik Tranberg A, Chaplin EJ, BolinK, MalmgrenK, et al. Socioeconomic outcome and access to care in adults with epilepsy in Sweden: a nationwide cohort study. Seizure. 2020;74:71-76.
Mattsson P, Tomson T, Eriksson O, Brannstrom L, Weitoft GR. Sociodemographic differences in antiepileptic drug prescriptions to adult epilepsy patients. Neurology. 2010;74(4):295-301.
Campbell E, Hunt S, Kinney MO, Guthrie E, Smithson WH, Parsons L, et al. The effect of socioeconomic status on treatment and pregnancy outcomes in women with epilepsy in Scotland. Epilepsy Behav. 2013;28(3):354-357.
Weston J, Bromley R, Jackson CF, Adab N, Clayton-Smith J, Greenhalgh J, et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev 2016;11(11):CD010224.
Christensen J, Pedersen L, Sun Y, Dreier JW, Brikell I, Dalsgaard S. Association of prenatal exposure to valproate and other antiepileptic drugs with risk for attention-deficit/hyperactivity disorder in offspring. JAMA Netw Open. 2019;2(1):e186606.
Elkjaer LS, Bech BH, Sun Y, Laursen TM, Christensen J. Association between prenatal valproate exposure and performance on standardized language and mathematics tests in school-aged children. JAMA Neurol. 2018;75(6):663-671.
Agency SMP. Läkemedelsbehandling av epilepsi- behandlingsrekommendation. Swedish Medical Products Agency. 2019. [updated 3 October 2019; cited 2020 22 February 2020]. https://lakemedelsverket.se/upload/halso-och-sjukvard/behandlingsrekommendationer/191003-Behandlingsrekommendation-Epilepsi.pdf
Charlton R, Damase-Michel C, Hurault-Delarue C, Gini R, Loane M, Pierini A, et al. Did advice on the prescription of sodium valproate reduce prescriptions to women? An observational study in three European countries between 2007 and 2016. Pharmacoepidemiol Drug Saf. 2019;28(11):1519-1528.
Kurvits K, Laius O, Uusküla M, Haldre S, Rakitin A. Valproic acid prescription trends among females of childbearing age in Estonia: a 14-year nationwide prescription database study. Seizure. 2020;76:28-31.
Virta LJ, Kälviäinen R, Villikka K, Keränen T. Declining trend in valproate use in Finland among females of childbearing age in 2012-2016 - a nationwide registry-based outpatient study. Eur J Neurol. 2018;25(6):869-874.
Karlsson Lind L, Komen J, Wettermark B, von Euler M, Tomson T. Valproic acid utilization among girls and women in Stockholm: impact of regulatory restrictions. Epilepsia Open. 2018;3(3):357-363.
Sveinsson O, Andersson T, Mattsson P, Carlsson S, Tomson T. Clinical risk factors in SUDEP: a nationwide population-based case-control study. Neurology. 2020;94(4):419-429.